A Phase 2 clinical trial to evaluate the safety and anti-tumor activity of the combination of Vigil EATC and Atezolizumab in women with advanced ovarian cancer.

Trial Profile

A Phase 2 clinical trial to evaluate the safety and anti-tumor activity of the combination of Vigil EATC and Atezolizumab in women with advanced ovarian cancer.

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs Atezolizumab (Primary) ; Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Gradalis
  • Most Recent Events

    • 28 Dec 2016 New trial record
    • 21 Dec 2016 According to Gradalis media release, company plans to initiate this trial early in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top